Show simple item record

SELECT-3: a phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting.

dc.contributor.authorDean, Emma J
dc.contributor.authorSteele, N
dc.contributor.authorArkenau, H
dc.contributor.authorBlackhall, Fiona H
dc.contributor.authorHaris, N
dc.contributor.authorLindsay, C
dc.contributor.authorRafii, S.
dc.contributor.authorCalifano, Raffaele
dc.contributor.authorPlummer, R
dc.contributor.authorVoskoboynik, M
dc.contributor.authorSummers, Yvonne J
dc.contributor.authorGhiorghiu, D
dc.contributor.authorDymond, A
dc.contributor.authorSo, K
dc.contributor.authorGreystoke, A
dc.date.accessioned2017-05-02T19:44:45Z
dc.date.available2017-05-02T19:44:45Z
dc.date.issued2016-10-01
dc.identifier.citationSELECT-3: a phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. 2016, 27(suppl 6):1269P Annals of Oncologyen
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.doi10.1093/annonc/mdw383.69
dc.identifier.urihttp://hdl.handle.net/10541/620306
dc.language.isoenen
dc.relation.urlhttps://academic.oup.com/annonc/article/2800162/SELECT-3:en
dc.rightsArchived with thanks to Annals of Oncologyen
dc.titleSELECT-3: a phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting.en
dc.typeMeetings and Proceedingsen
dc.identifier.journalAnnals of Oncologyen


This item appears in the following Collection(s)

Show simple item record